Media stories about NxStage Medical (NASDAQ:NXTM) have been trending somewhat positive on Saturday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. NxStage Medical earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 46.1052221693873 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Stock Watch: Signals in View for Nxstage Medical Inc (NXTM) – Lockport Press (lockportpress.com)
- Eleven Unique NxStage Abstracts Accepted for 2017 Kidney Week (finance.yahoo.com)
- These Stock’s are Flying High, But Don’t Go Contrarian Yet: Nxstage Medical, Inc., (NASDAQ: NXTM), Golden Star … – Stocks In The News (press release) (tradingnewsnow.com)
- Featured Company News – Shareholders of NxStage Approve Merger with Fresenius Medical Care (finance.yahoo.com)
- Brokerages Expect NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 Million (americanbankingnews.com)
Several research firms recently issued reports on NXTM. William Blair lowered NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, August 7th. Jefferies Group LLC lowered NxStage Medical from a “buy” rating to a “hold” rating and reduced their price target for the stock from $33.00 to $30.00 in a research report on Tuesday, August 8th. Stephens lowered NxStage Medical from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $33.00 to $30.00 in a research report on Wednesday, August 9th. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research report on Thursday, August 10th. Finally, BTIG Research lowered NxStage Medical from a “buy” rating to a “neutral” rating in a research report on Friday, August 11th. Two investment analysts have rated the stock with a sell rating and eight have given a hold rating to the stock. NxStage Medical presently has an average rating of “Hold” and a consensus target price of $30.25.
Shares of NxStage Medical (NXTM) traded down $0.18 during mid-day trading on Friday, hitting $26.65. The stock had a trading volume of 382,030 shares, compared to its average volume of 655,331. NxStage Medical has a 12-month low of $20.45 and a 12-month high of $30.80.
NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). The company had revenue of $92.20 million during the quarter, compared to analysts’ expectations of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period last year, the business earned ($0.03) EPS. equities research analysts anticipate that NxStage Medical will post -0.06 earnings per share for the current year.
In related news, President Joseph E. Turk, Jr. sold 24,000 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $29.64, for a total value of $711,360.00. Following the completion of the transaction, the president now directly owns 82,903 shares of the company’s stock, valued at $2,457,244.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $29.26, for a total transaction of $29,260.00. Following the completion of the transaction, the president now directly owns 74,903 shares of the company’s stock, valued at $2,191,661.78. The disclosure for this sale can be found here. Insiders sold 42,600 shares of company stock valued at $1,237,522 over the last three months. 4.70% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “NxStage Medical (NXTM) Receiving Somewhat Positive Media Coverage, Study Shows” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/04/nxstage-medical-nxtm-receiving-somewhat-positive-media-coverage-study-shows.html.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
What are top analysts saying about NxStage Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NxStage Medical Inc. and related companies.